» Articles » PMID: 33790708

Severe Hypertriglyceridemia-Induced Acute Pancreatitis

Overview
Publisher Karger
Specialty Gastroenterology
Date 2021 Apr 1
PMID 33790708
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of familial hypercholesterolemia (FH) is about 1 in 200-500 in the general population, but approximately less than 1% of those affected are actually diagnosed. One of the most promising approaches to treat FH is utilizing human monoclonal antibodies. This is a case study describing a 47-year-old male patient who presented to the Emergency Department with acute abdominal pain caused by severe hypertriglyceridemia (HTG)-induced acute pancreatitis (AP). We report the steps necessary for establishing the right diagnosis and the management of HTG-induced AP, which are inevitable for the reduction of severity and mortality. This case study shows that hypercholesterolemia is an underdiagnosed and potentially lethal disease. Once diagnosed, all measures should be considered to control blood cholesterol and lipid levels. The decision to administer PCSK9 inhibitors should not be solely based on economical calculation, but rather individual factors should also be considered to weigh the risk/benefit ratio.

Citing Articles

Sonographic "Comet Tail" Artifacts in the Urinary Bladder in a Case of Type V Hyperlipidemia: A Previously Unreported Association.

Lahel R, Mathur S J Med Ultrasound. 2025; 32(4):334-336.

PMID: 39801552 PMC: 11717083. DOI: 10.4103/jmu.jmu_79_23.


A nomogram for predicting in-hospital overall survival of hypertriglyceridemia-induced severe acute pancreatitis: A single center, cross-sectional study.

Wu H, Liao B, Ji T, Jia S, Luo Y, Ma K Heliyon. 2024; 10(1):e23454.

PMID: 38173503 PMC: 10761568. DOI: 10.1016/j.heliyon.2023.e23454.

References
1.
Ogura M . PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2017; 71(1):1-7. DOI: 10.1016/j.jjcc.2017.07.002. View

2.
McDonagh M, Peterson K, Holzhammer B, Fazio S . A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. J Manag Care Spec Pharm. 2016; 22(6):641-653q. PMC: 10397903. DOI: 10.18553/jmcp.2016.22.6.641. View

3.
Banks P, Bollen T, Dervenis C, Gooszen H, Johnson C, Sarr M . Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2012; 62(1):102-11. DOI: 10.1136/gutjnl-2012-302779. View

4.
Olry de Labry Lima A, Gimeno Ballester V, Sierra Sanchez J, Hoces A, Gonzalez-Outon J, Del Rey E . Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain. Rev Esp Cardiol (Engl Ed). 2018; 71(12):1027-1035. DOI: 10.1016/j.rec.2018.05.003. View

5.
Mytilinaiou M, Kyrou I, Khan M, Grammatopoulos D, Randeva H . Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. Front Pharmacol. 2018; 9:707. PMC: 6052892. DOI: 10.3389/fphar.2018.00707. View